Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arcutis Biotherapeutics (Nasdaq: ARQT) has announced the grant of 27,000 restricted stock units to three newly hired employees. The grants were approved by the company's Compensation Committee and issued under the Arcutis Biotherapeutics 2022 Inducement Plan on March 3, 2025.
The restricted stock units feature a four-year vesting schedule, with 25% vesting annually on each anniversary of the vesting commencement date. Continued employment with Arcutis is required for vesting. The grants were made as employment inducements in compliance with Nasdaq Listing Rule 5635(c)(4).
Arcutis Biotherapeutics (Nasdaq: ARQT) ha annunciato l'assegnazione di 27.000 unità di azioni riservate a tre nuovi dipendenti. Le assegnazioni sono state approvate dal Comitato per la Compensazione dell'azienda e emesse nell'ambito del Piano di Induzione 2022 di Arcutis Biotherapeutics il 3 marzo 2025.
Le unità di azioni riservate prevedono un programma di maturazione di quattro anni, con il 25% che matura annualmente ad ogni anniversario della data di inizio della maturazione. È richiesta la continuazione dell'impiego con Arcutis per la maturazione. Le assegnazioni sono state effettuate come incentivi all'occupazione in conformità con la Regola di Quotazione Nasdaq 5635(c)(4).
Arcutis Biotherapeutics (Nasdaq: ARQT) ha anunciado la concesión de 27,000 unidades de acciones restringidas a tres empleados recién contratados. Las concesiones fueron aprobadas por el Comité de Compensación de la empresa y emitidas bajo el Plan de Inducción 2022 de Arcutis Biotherapeutics el 3 de marzo de 2025.
Las unidades de acciones restringidas cuentan con un cronograma de adquisición de cuatro años, con un 25% que se adquiere anualmente en cada aniversario de la fecha de inicio de la adquisición. Se requiere continuar el empleo con Arcutis para la adquisición. Las concesiones se realizaron como incentivos de empleo en cumplimiento con la Regla de Cotización Nasdaq 5635(c)(4).
Arcutis Biotherapeutics (Nasdaq: ARQT)는 세 명의 신규 직원에게 27,000개의 제한 주식 단위를 부여했다고 발표했습니다. 이 부여는 회사의 보상 위원회에 의해 승인되었으며, 2022년 Arcutis Biotherapeutics 유도 계획에 따라 2025년 3월 3일에 발행되었습니다.
제한 주식 단위는 4년의 취득 일정을 특징으로 하며, 매년 취득 시작일의 기념일에 25%가 취득됩니다. 취득을 위해서는 Arcutis에서의 지속적인 고용이 필요합니다. 이 부여는 Nasdaq 상장 규칙 5635(c)(4)에 따라 고용 유인을 위해 이루어졌습니다.
Arcutis Biotherapeutics (Nasdaq: ARQT) a annoncé l'octroi de 27 000 unités d'actions restreintes à trois nouveaux employés. Les octrois ont été approuvés par le Comité de Rémunération de l'entreprise et émis dans le cadre du Plan d'Induction 2022 d'Arcutis Biotherapeutics le 3 mars 2025.
Les unités d'actions restreintes comportent un calendrier d'acquisition de quatre ans, avec 25 % d'acquisition annuelle à chaque anniversaire de la date de début de l'acquisition. Un emploi continu avec Arcutis est requis pour l'acquisition. Les octrois ont été effectués comme incitations à l'emploi conformément à la règle de cotation Nasdaq 5635(c)(4).
Arcutis Biotherapeutics (Nasdaq: ARQT) hat die Gewährung von 27.000 eingeschränkten Aktieneinheiten an drei neu eingestellte Mitarbeiter angekündigt. Die Gewährungen wurden vom Vergütungsausschuss des Unternehmens genehmigt und wurden am 3. März 2025 im Rahmen des Arcutis Biotherapeutics 2022 Induktionsplans ausgegeben.
Die eingeschränkten Aktieneinheiten haben einen Vesting-Zeitplan von vier Jahren, wobei 25% jährlich am Jahrestag des Vesting-Startdatums fällig werden. Eine fortgesetzte Beschäftigung bei Arcutis ist für das Vesting erforderlich. Die Gewährungen wurden als Beschäftigungsanreize in Übereinstimmung mit der Nasdaq-Listing-Regel 5635(c)(4) vorgenommen.
- None.
- None.
WESTLAKE VILLAGE, Calif., March 05, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 27,000 restricted stock units of Arcutis’ common stock to three newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of March 3, 2025, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).
The restricted stock units vest over four years, with 25 percent vesting on each annual anniversary of the vesting commencement date, subject to the employee being continuously employed by Arcutis as of such vesting dates.
Arcutis is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Arcutis
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio including three FDA approved products that harness our unique dermatology development platform coupled with our dermatology expertise to build differentiated therapies against biologically validated targets. Arcutis’ dermatology development platform includes a robust pipeline with multiple clinical programs for a range of inflammatory dermatological conditions including scalp and body psoriasis, atopic dermatitis, and alopecia areata. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, and X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. For example, statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations. These statements are subject to substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in our business, reimbursement and access to our products, the impact of competition and other important factors discussed in the “Risk Factors” section of our Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 25, 2025, as well as any subsequent filings with the SEC. Any forward-looking statements that the company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, we undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.
Contacts:
Media
Amanda Sheldon, Head of Corporate Communications
media@arcutis.com
Investors
Latha Vairavan, Vice President, Finance and Corporate Controller
ir@arcutis.com
FAQ
How many restricted stock units did Arcutis Biotherapeutics (ARQT) grant in March 2025?
What is the vesting schedule for ARQT's March 2025 restricted stock units?
Under which plan were ARQT's March 2025 stock grants issued?
What is the purpose of ARQT's March 2025 restricted stock unit grants?
